Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 2, 2024
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 2, 2024
Mavenir’s Energy-Efficient 5G UPF Solution Wins Leading Lights Network Energy Efficiency Award October 2, 2024
Mavenir’s Energy-Efficient 5G UPF Solution Wins Leading Lights Network Energy Efficiency Award October 2, 2024
Main Committee Convenes to Discuss E-Census Implementation in Agricultural, Fisheries, and Water Sectors March 19, 2025
